Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 31

References for PMC Articles for PubMed (Select 21637807)

1.

Drugs in development for tuberculosis.

Ginsberg AM.

Drugs. 2010 Dec 3;70(17):2201-14. doi: 10.2165/11538170-000000000-00000. Review.

PMID:
21080738
2.

In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.

Pucci MJ, Ackerman M, Thanassi JA, Shoen CM, Cynamon MH.

Antimicrob Agents Chemother. 2010 Aug;54(8):3478-80. doi: 10.1128/AAC.00287-10. Epub 2010 Jun 1.

3.

Extensively drug-resistant tuberculosis: "there must be some kind of way out of here".

Cegielski JP.

Clin Infect Dis. 2010 May 15;50 Suppl 3:S195-200. doi: 10.1086/651491. Review.

4.

Tuberculosis drug development: progress, challenges, and the road ahead.

Ginsberg AM.

Tuberculosis (Edinb). 2010 May;90(3):162-7. doi: 10.1016/j.tube.2010.03.003. Epub 2010 Apr 9. Review.

PMID:
20382086
5.

The alanine racemase of Mycobacterium smegmatis is essential for growth in the absence of D-alanine.

Milligan DL, Tran SL, Strych U, Cook GM, Krause KL.

J Bacteriol. 2007 Nov;189(22):8381-6. Epub 2007 Sep 7.

6.

Key issues in multidrug-resistant tuberculosis.

Chakrabarti B, Davies PD.

Future Microbiol. 2007 Feb;2(1):51-61. Review.

PMID:
17661675
7.

Barriers to reaching the targets for tuberculosis control: multidrug-resistant tuberculosis.

Blöndal K.

Bull World Health Organ. 2007 May;85(5):387-90; discussion 391-4.

8.

New tuberculosis drugs in development.

Laughon BE.

Curr Top Med Chem. 2007;7(5):463-73. Review.

PMID:
17346192
9.

Challenges in tuberculosis drug research and development.

Ginsberg AM, Spigelman M.

Nat Med. 2007 Mar;13(3):290-4. Review. No abstract available.

PMID:
17342142
10.

The 1.9 A crystal structure of alanine racemase from Mycobacterium tuberculosis contains a conserved entryway into the active site.

LeMagueres P, Im H, Ebalunode J, Strych U, Benedik MJ, Briggs JM, Kohn H, Krause KL.

Biochemistry. 2005 Feb 8;44(5):1471-81.

PMID:
15683232
11.

Reaction specificity in pyridoxal phosphate enzymes.

Toney MD.

Arch Biochem Biophys. 2005 Jan 1;433(1):279-87. Review.

PMID:
15581583
12.

Molecular dynamics studies of alanine racemase: a structural model for drug design.

Mustata GI, Soares TA, Briggs JM.

Biopolymers. 2003 Oct;70(2):186-200.

PMID:
14517907
13.
14.

The growing burden of tuberculosis: global trends and interactions with the HIV epidemic.

Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, Dye C.

Arch Intern Med. 2003 May 12;163(9):1009-21. Review.

PMID:
12742798
15.

A side reaction of alanine racemase: transamination of cycloserine.

Fenn TD, Stamper GF, Morollo AA, Ringe D.

Biochemistry. 2003 May 20;42(19):5775-83.

PMID:
12741835
16.

N(2)-substituted D,L-cycloserine derivatives: synthesis and evaluation as alanine racemase inhibitors.

Kim MG, Strych U, Krause K, Benedik M, Kohn H.

J Antibiot (Tokyo). 2003 Feb;56(2):160-8.

17.

Genes required for mycobacterial growth defined by high density mutagenesis.

Sassetti CM, Boyd DH, Rubin EJ.

Mol Microbiol. 2003 Apr;48(1):77-84.

PMID:
12657046
18.

A model for enzyme-substrate interaction in alanine racemase.

Ondrechen MJ, Briggs JM, McCammon JA.

J Am Chem Soc. 2001 Mar 28;123(12):2830-4.

PMID:
11456969
19.

Characterization of the alanine racemases from two mycobacteria.

Strych U, Penland RL, Jimenez M, Krause KL, Benedik MJ.

FEMS Microbiol Lett. 2001 Mar 15;196(2):93-8.

20.

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

Lipinski CA, Lombardo F, Dominy BW, Feeney PJ.

Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26. Review.

PMID:
11259830
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk